Immutep, Monash Reveal LAG-3 Binding to MHC Class II

Clinical-stage company Immutep (ASX:IMM) has announced new findings published in Science Immunology that resolve how human lymphocyte activation gene 3 (LAG-3) binds to its main ligand MHC Class II (MHC-II), also known as HLA Class II (HLA-II) in humans.

Immutep is developing novel LAG-3 immunotherapies for cancer and autoimmune diseases.

The company said the publication is the first to show the crystal structure of a human LAG-3/HLA-II complex and provides a better foundation for the development of blocking LAG-3 therapeutics, including Immutep's anti-LAG-3 small molecule program. It said the data supports its efti's (soluble LAG-3) preferential binding to a subset of MHC-II molecules on antigen-presenting cells, leading to their activation.

Dr Jan Petersen, first author of the study, said, "The way the PD-1 and CTLA-4 immune checkpoint molecules bind to their respective ligands has been resolved for many years. However, the resolution of the interface between another important checkpoint molecule, LAG-3, and its main ligands, HLA-II molecules, has remained elusive. Solved using data collected at the Australian Synchrotron, a structure of a LAG-3/HLA-II complex provides a structural foundation to harness rationally for future development of antibodies and small molecule therapeutics designed to block LAG-3 activity."

Immuntep CSO Dr Frédéric Triebel, Immutep's CSO, added, "It is thrilling to be able to see and analyse the interactions taking place at the interface between the soluble homodimeric LAG-3 protein and its main ligand. We now better understand how efti uniquely acts as an MHC-II agonist by preferentially binding to a subset of MHC-II molecules clustered in lipid raft microdomains on the surface of antigen-presenting cells. These findings add to the strong foundation of our work with Professor Rossjohn and his team to develop a deeper understanding of the structure and function of the LAG-3 immune control mechanism, particularly as it relates to our anti-LAG-3 small molecule program."

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.